FindTrial
Sign In

Evaluation of the safety and efficacy of loading dose of Ticagrelor in patients with acute ST-segment elevation myocardial infarction with intravenous thrombolysis

Evaluation of the safety and efficacy of loading dose of Ticagrelor in patients with acute ST-segment elevation myocardial infarction with intravenous thrombolysis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-17012036
Enrollment
Unknown
Registered
2017-07-18
Start date
2017-07-11
Completion date
Unknown
Last updated
2017-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Heart Disease

Interventions

Group B:aspirin enteric-coated tablets 300mg + clopidogrel sulfate tablets 300mg, then, injection recombinant urokinase thrombolysis
Group A:aspirin enteric-coated tablets 300mg + clopidogrel tablets 180mg, then, injection recombinant urokinase thrombolysis

Sponsors

Department of Cardiology,the Second Hospital of Hebei Medical University, Shijiazhuang City, Hebei Province
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Acute ST-segment elevation myocardial infarction onset time is less than 12 hours, FMC is expected to first medical contact) to PCI time delay greater than 120min, no thrombolysis contraindications; 2. Incidence of 12-24 hours of progressive ischemic chest pain and at least 2 thoracic lead or limb lead ST-segment elevation> 0.1mV, or hemodynamic instability in patients without direct PCI condition.

Exclusion criteria

Exclusion criteria: 1. thrombolysis contraindications; 2. with direct PCI condition.

Design outcomes

Primary

MeasureTime frame
ECG;—

Contacts

Public ContactWang Mei

Department of Cardiology, the Second Hospital of Hebei Medical University

wangmei86632@sina.com+86 13313038682

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026